DZ3042A1 - Dérivés d'isothiazole nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. - Google Patents

Dérivés d'isothiazole nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.

Info

Publication number
DZ3042A1
DZ3042A1 DZ000085A DZ000085A DZ3042A1 DZ 3042 A1 DZ3042 A1 DZ 3042A1 DZ 000085 A DZ000085 A DZ 000085A DZ 000085 A DZ000085 A DZ 000085A DZ 3042 A1 DZ3042 A1 DZ 3042A1
Authority
DZ
Algeria
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
isothiazole derivatives
new
Prior art date
Application number
DZ000085A
Other languages
English (en)
Inventor
Thomas George Gant
Mark Cari Noe
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DZ3042A1 publication Critical patent/DZ3042A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
DZ000085A 1999-05-19 2000-05-17 Dérivés d'isothiazole nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. DZ3042A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13493399P 1999-05-19 1999-05-19

Publications (1)

Publication Number Publication Date
DZ3042A1 true DZ3042A1 (fr) 2004-03-27

Family

ID=22465672

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ000085A DZ3042A1 (fr) 1999-05-19 2000-05-17 Dérivés d'isothiazole nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.

Country Status (21)

Country Link
US (1) US6380214B1 (fr)
EP (1) EP1187826B1 (fr)
JP (2) JP3692041B2 (fr)
AR (1) AR029634A1 (fr)
AT (1) ATE349440T1 (fr)
AU (1) AU4137400A (fr)
BR (1) BR0010746A (fr)
CA (1) CA2374247C (fr)
CO (1) CO5170417A1 (fr)
DE (1) DE60032601T2 (fr)
DZ (1) DZ3042A1 (fr)
ES (1) ES2276681T3 (fr)
GT (1) GT200000069A (fr)
HN (1) HN2000000051A (fr)
MA (1) MA26733A1 (fr)
MX (1) MXPA01011920A (fr)
PA (1) PA8494101A1 (fr)
PE (1) PE20010152A1 (fr)
TN (1) TNSN00104A1 (fr)
UY (1) UY26143A1 (fr)
WO (1) WO2000071532A1 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP2298311B1 (fr) 1999-01-13 2012-05-09 Bayer HealthCare LLC Urées de diphényle à substitution omega-carboxyaryle en tant qu'inhibiteurs de la p38 kinase
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2001057034A1 (fr) 2000-02-07 2001-08-09 Bristol-Myers Squibb Co. Inhibiteurs 3-aminopyrazole des kinases dependantes des cyclines
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US8329924B2 (en) * 2001-06-11 2012-12-11 Vertex Pharmaceuticals (Canada) Incorporated Compounds and methods for the treatment or prevention of Flavivirus infections
EP2363396A1 (fr) * 2001-06-11 2011-09-07 Virochem Pharma Inc. Dérivés de thiophène comme agents antivirales contre des infections par flavivirus
SE0102617D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
WO2003068229A1 (fr) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation N-oxydes de pyridine, de quinoline, et d'isoquinoline en tant qu'inhibiteurs de kinase
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
US6989451B2 (en) * 2002-06-04 2006-01-24 Valeant Research & Development Heterocyclic compounds and uses thereof
EP1521577A1 (fr) * 2002-06-13 2005-04-13 QLT, Inc. Procedes d'utilisation de derives d'izothiazole pour traiter un cancer ou une inflammation
US20060135568A1 (en) * 2002-07-09 2006-06-22 Townsend Craig A Methods of treating microbial infections in humans and animals
US7649012B2 (en) * 2002-07-09 2010-01-19 Fasgen, Inc. Compounds, pharmaceutical compositions containing same, and methods of use for same
CA2493701A1 (fr) * 2002-07-25 2004-02-05 Pfizer Products Inc. Derives isothiazoles utiles en tant qu'agents anticancereux
AU2003302665B2 (en) * 2002-11-15 2009-12-24 Symphony Evolution, Inc. Kinase modulators
DE60332482D1 (de) 2002-12-10 2010-06-17 Virochem Pharma Inc Verbindungen und methoden zum behandeln oder vorbeugen von flavivirus infektionen
SE0300092D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300091D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
EP1602647B1 (fr) * 2003-03-07 2013-10-16 Santen Pharmaceutical Co., Ltd. Nouveau compose comprenant un groupe 4-pyridylalkylthio utilise comme substitutif
EP1636585B2 (fr) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl-urees presentant une activite d'inhibition des kinases
PL1663978T3 (pl) 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
JP4626353B2 (ja) * 2004-02-17 2011-02-09 参天製薬株式会社 置換又は無置換アミノ基を導入した４−ピリジルアルキルチオ基を有する新規環式化合物
ES2368153T3 (es) * 2004-02-17 2011-11-14 Santen Pharmaceutical Co., Ltd. Nuevo compuesto cíclico que presenta un grupo 4-piridilalquiltio que presenta amino (no) sustituido introducido en el mismo.
US7544703B2 (en) * 2004-02-17 2009-06-09 Santen Pharmaceutical Co., Ltd. Cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein
CA2560510C (fr) 2004-03-18 2009-10-13 Pfizer Inc. Sulfamides n-(1-arylpyrazol-4yl) et leur utilisation en tant qu'anti-parasitaires
US7838524B2 (en) 2004-04-30 2010-11-23 Bayer Healthcare Llc Substituted pyrazolyl urea derivatives useful in the treatment of cancer
CN101043888B (zh) 2004-08-26 2010-08-11 辉瑞有限公司 制备异噻唑衍生物的方法
JP4585978B2 (ja) * 2005-03-03 2010-11-24 参天製薬株式会社 キノリルアルキルチオ基を有する新規環式化合物
JP5030947B2 (ja) * 2005-05-13 2012-09-19 ヴァイロケム・ファーマ・インコーポレーテッド フラビウイルス感染の治療及び予防のための化合物及び方法
US7932390B2 (en) 2006-06-29 2011-04-26 Hoffman-La Roche Inc. Substituted thieno[3,2-C]pyridine carboxylic acid derivatives
SG176488A1 (en) * 2006-11-15 2011-12-29 Virochem Pharma Inc Thiophene analogues for the treatment or prevention of flavivirus infections
KR20090115749A (ko) 2007-02-26 2009-11-05 산텐 세이야꾸 가부시키가이샤 우레이드기와 아미노카르보닐기를 치환기로서 갖는 신규 피롤 유도체
TW200911240A (en) * 2007-06-11 2009-03-16 Kyowa Hakko Kogyo Kk Anti-tumor agent
MX2010001636A (es) 2007-08-14 2010-03-15 Hoffmann La Roche Derivados de pirazolo[3,4-d]-pirimidina como agentes antiproliferativos.
WO2010151710A2 (fr) * 2009-06-25 2010-12-29 Medolution Limited Composés hétérocycliques substitués utilisés en tant qu'inhibiteurs de la kinase et leur procédé d'utilisation
CN104302640A (zh) 2012-03-16 2015-01-21 埃克希金医药品有限公司 3,5-二氨基吡唑激酶抑制剂
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
MY191736A (en) 2014-12-23 2022-07-13 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
CN118221635B (zh) * 2024-03-21 2026-06-26 沈阳药科大学 芳基噻吩类化合物及其制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1950990A1 (de) * 1968-10-17 1970-05-14 Ciba Geigy Verfahren zur Herstellung von neuen triazacyclischen Verbindungen
GB1355513A (en) * 1971-04-07 1974-06-05 May & Baker Ltd Isothiazole derivatives
DE2408234A1 (de) * 1974-02-21 1975-09-04 Celamerck Gmbh & Co Kg Isothiazolylharnstoffe
US4059433A (en) * 1976-06-18 1977-11-22 Fmc Corporation 3-Alkoxyisothiazole derivatives as herbicides
US4075001A (en) * 1976-06-18 1978-02-21 Fmc Corporation 3-Aminoisothiazole derivatives as herbicides
US4057416A (en) * 1976-06-18 1977-11-08 Fmc Corporation 3-Alkylthio-, 3-alkylsulfinyl-, and 3-alkylsulfonylisothiazole derivatives as herbicides
DE3529247A1 (de) * 1985-05-17 1986-11-20 Bayer Ag, 5090 Leverkusen Verwendung von thienylharnstoffen und -isoharnstoffen als leistungsfoerdernde mittel bei tieren, neue thienylharnstoffe und -isoharnstoffe und ihre herstellung
DE3540377A1 (de) * 1985-11-14 1987-05-21 Bayer Ag Thienooxazinone, verfahren zu ihrer herstellung und ihre verwendung als leistungsfoerderer
DE3541631A1 (de) * 1985-11-26 1987-05-27 Bayer Ag Selektiv-fungizide verwendung von thienylharnstoff-derivaten
US4859699A (en) * 1987-07-20 1989-08-22 Sandoz Ltd. Substituted N-benzoyl-N'-thienylureas
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
DE4328425A1 (de) * 1993-08-24 1995-03-02 Basf Ag Acylamino-substituierte Isoxazol- bzw. Isothiazolderivate, Verfahren zu deren Herstellung und ihre Verwendung
TW276256B (fr) * 1993-08-26 1996-05-21 Takeda Pharm Industry Co Ltd
CA2203517A1 (fr) * 1994-11-10 1996-05-23 Alan M. Laibelman Compositions pharmaceutiques a base de pyrazole, agissant comme inhibiteurs des proteines kinases
US5792767A (en) * 1995-01-27 1998-08-11 Abbott Laboratories Bicyclic substituted hexahydrobenz e! isoindole alpha-1 adrenergic antagonists
US5773459A (en) * 1995-06-07 1998-06-30 Sugen, Inc. Urea- and thiourea-type compounds
AU7585598A (en) * 1997-05-23 1998-12-11 Bayer Corporation Raf kinase inhibitors
US6037340A (en) * 1997-05-28 2000-03-14 Cadus Pharmaceutical Corporation Synthesis and use of thiophene- and pyrrole-based heteroaromatic compounds
UA60365C2 (uk) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця

Also Published As

Publication number Publication date
BR0010746A (pt) 2002-02-13
MA26733A1 (fr) 2004-12-20
TNSN00104A1 (fr) 2005-11-10
AR029634A1 (es) 2003-07-10
JP2003500401A (ja) 2003-01-07
US6380214B1 (en) 2002-04-30
JP3692041B2 (ja) 2005-09-07
PA8494101A1 (es) 2003-09-05
ES2276681T3 (es) 2007-07-01
MXPA01011920A (es) 2002-05-06
HN2000000051A (es) 2001-02-02
EP1187826A1 (fr) 2002-03-20
DE60032601D1 (de) 2007-02-08
PE20010152A1 (es) 2001-02-08
UY26143A1 (es) 2000-12-29
ATE349440T1 (de) 2007-01-15
CA2374247C (fr) 2008-01-22
WO2000071532A1 (fr) 2000-11-30
AU4137400A (en) 2000-12-12
EP1187826B1 (fr) 2006-12-27
CO5170417A1 (es) 2002-06-27
DE60032601T2 (de) 2007-11-15
CA2374247A1 (fr) 2000-11-30
JP2005008641A (ja) 2005-01-13
GT200000069A (es) 2001-11-08

Similar Documents

Publication Publication Date Title
MA26659A1 (fr) Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
DZ2891A1 (fr) Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3009A1 (fr) Dérivés de quinoléine-2-one à substituant hétéroaryle nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3020A1 (fr) Acides oxamiques nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3045A1 (fr) Dérivés de i 3-méthyl-érythromycine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2963A1 (fr) Dérivés de bicycliques substituées nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ1889A1 (fr) Dérivés de quinoléine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2300A1 (fr) Dérivés 6,5-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2299A1 (fr) Dérivés 6,6-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26638A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compoositions pharmaceutiques les contenant
DZ1957A1 (fr) Dérivés de pipéridine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2197A1 (fr) Dérivés de 6-phénylpyridyl-2-amine, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2303A1 (fr) Dérivés d'indazole nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2870A1 (fr) Dérivés d'acide hydroxypipécolate-hydroxamique nouveaux, procédé pour leur préparation et compositi ons pharmaceutiques les contenant.
DZ2777A1 (fr) Dérivés de quinazolinamines nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2227A1 (fr) Dérivés d'indole nouveaux, procédé pour leur préparation et formulations pharmaceutiques les contenant.
DZ2581A1 (fr) Dérivés d'acides aryloxyarylsulfonylaminohydroxamiques procédé pour leur préparation et compositionspharmaceutiques les contenant.
DZ2758A1 (fr) Dérivés bicycliques d0acide hydroxamique nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2890A1 (fr) 4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2962A1 (fr) Dérivés de 3-azabicycloÄ3,1,0Ühexane nouveaux, procédé pour leur préparation et compositions les contenant.
DZ2745A1 (fr) BicycloÄ2.2.1Üheptanes nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2699A1 (fr) Dérivés d'érythromycine nouveaux procédé et intermédiaires pour préparation et compositions pharmaceutiques les contenant.
DZ2773A1 (fr) Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2666A1 (fr) Dérivés d'acide hydroxamique compositions pharmaceutiques les contenant et procédé pour leur préparation.
DZ2880A1 (fr) Dérivés de quinoléine-2-one à substituant alcynylenouveaux procédé pour leur préparation et composi tions pharmaceutiques les contenant.